Evaluating Tolerability of ePUHRT With Brachytherapy Boost

The purpose of this study is to evaluate the tolerability and toxicity of combining two radiation therapy methods for prostate cancer: Elective Pelvic Ultra Hypofractionated Irradiation Treatment (ePUHRT), which is an external beam radiotherapy with High Dose Rate Brachytherapy Boost (form of internal radiation where a cancer doctor implants a small plastic tube or balloon (catheter) in the tumor).

Trial Details

NCT ID
NCT06817668
Phase
NA
Sponsor
Indiana University
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • ePURT 5Gy x 5 fractions with single HDR boost of 15Gy
Locations (sample)
  • Indianapolis, Indiana, United States|39.76838,-86.15804

Key Eligibility Criteria

  • ≥ 18 years old at the time of informed consent
  • Capable of providing informed consent and HIPAA authorization
  • Karnofsky performance score ≥ 70
  • Pathologically confirmed unfavorable intermediate, high, and very high-risk prostate cancer per treating physician

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →